The collaborations include a drug discovery project with Western University; a co-development project with Delmar Chemicals; and a drug discovery project with a major global pharmaceutical company.
Critical Outcome Technologies president and CEO Wayne Danter said that success with these projects will provide ongoing independent third party validation of Chemsas as a powerful artificial intelligence drug discovery engine across multiple targets and as a commercial asset.
"Each of these co-development discovery projects has significant revenue generating potential, and based upon recently completing a few pilot projects, we are seeking to add additional collaborations during 2013," Danter added.